7,416.29

+62.56

+0.85%

51,547.32

+24.26

+0.05%

24,695.94

+380.94

+1.57%

2,750.94

+21.05

+0.77%

4.8490

+0.0120

+0.25%

24.48

-3.70

-13.15%

4,068.20

-45.30

-1.10%

75,846.58

+159.87

+0.21%

Crude Oil Dec 26

90.05

-0.47

-0.52%

US Private Equity

10,760.93

-143.81

-1.32%

Breaking One day after a $2.3T market sell-off, U.S. October jobs report blows past estimates

NasdaqCM - Nasdaq Real Time Price USD

Curis, Inc. (CRIS)

0.8952 +0.0452 (+5.32%)

As of 12:19:33 PM EST. Market Open.

Loading Chart for CRIS

Chart Range Bar

Interval:

In partnership with ChartIQ

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

BC-Most Active Stocks

BC-Most Active Stocks

Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract Investors

Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract Investors

Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine

VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis Doses First Five Patients in TakeAim CLL Study

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Mobilize your Website

View Site in Mobile | Classic

Share by: